BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Neurofibromatosis Type 2 (NF2) is a dominantly inherited tumour-prone disorder, characterized by the development of multiple schwannomas, meningiomas and ependymomas.

A well-circumscribed heterogenic mass (9.5 × 4 × 4 cm) behind and under the left kidney and extending into the left retroperitoneal space was revealed during a lumbar and retroperitoneal space magnetic resonance imaging (MRI).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurooncol. 2009 May;93(1):61-77 [19430883.001]

[Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]

[Cites] World J Gastroenterol. 2007 Nov 7;13(41):5521-4 [17907300.001]

[Cites] Curr Probl Cancer. 1981 Jul;6(1):1-47 [6266775.001]

[Cites] Orphanet J Rare Dis. 2009 Jun 19;4:16 [19545378.001]

[Cites] Tumori. 2007 May-Jun;93(3):312-5 [17679473.001]

[Cites] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]

[Cites] J Neurosurg. 2003 Sep;99(3):480-3 [12959433.001]

[Cites] Arch Ophthalmol. 2006 Mar;124(3):379-85 [16534058.001]

(PMID = 28657039.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; meningioma / neurofibromatosis Type 2 / retroperitoneal / schwannoma

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CFTR structure and function: is there a role in the kidney?

Despite of the expression of CFTR in the kidney, patients with CF do not present major renal dysfunction, but it is known that both the urinary excretion of proteins and renal capacity to concentrate and dilute urine are altered in these patients.

CFTR mRNA is expressed in all nephron segments of rat and human, and this abundance is more prominent in renal cortex and outer medulla renal areas.

CFTR protein was detected in apical surface of both proximal and distal tubules of rat kidney but not in the outer medullary collecting ducts.

ATP transport by CFTR could be involved in the control of other ion transporters such as Na⁺ (ENaC) and K⁺ (renal outer medullary potassium) channels, especially in TAL and CCD.

In the kidney, CFTR also might be involved in the endocytosis of low-molecular-weight proteins by proximal tubules.

This review is focused on the CFTR function and structure, its role in the renal physiology, and its modulation by hormones involved in the control of extracellular fluid volume.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Physiol Rev. 1999 Jan;79(1 Suppl):S175-91 [9922381.001]

[Cites] Nephron. 1975;15(3-5):223-49 [1101087.001]

[Cites] Science. 1989 Sep 8;245(4922):1059-65 [2772657.001]

[Cites] J Biol Chem. 2002 May 3;277(18):15419-25 [11861646.001]

[Cites] Am J Physiol. 1998 May;274(5 Pt 2):F817-33 [9612319.001]

[Cites] J Clin Invest. 1998 Jul 1;102(1):15-21 [9649552.001]

[Cites] Am J Physiol. 1984 Jun;246(6 Pt 2):F745-56 [6377912.001]

[Cites] Am J Physiol. 1996 Jun;270(6 Pt 2):F1038-48 [8764323.001]

[Cites] Am J Physiol. 1999 Oct;277(4 Pt 2):F552-9 [10516279.001]

[Cites] Pflugers Arch. 1999 Oct;438(5):621-7 [10555558.001]

[Cites] Pflugers Arch. 2002 May;444(1-2):193-201 [11976932.001]

[Cites] Biochem J. 2007 Jan 15;401(2):581-6 [16989640.001]

[Cites] Hosp Pract (Off Ed). 1990 Oct 15;25(10):47-57 [1698801.001]

[Cites] Methods Enzymol. 2005;400:542-57 [16399369.001]

[Cites] FASEB J. 1992 Jun;6(9):2660-6 [1377140.001]

[Cites] Nature. 1985 Nov 28-Dec 4;318(6044):380-2 [2999611.001]

[Cites] Annu Rev Physiol. 1997;59:413-36 [9074771.001]

[Cites] Science. 1989 Sep 8;245(4922):1066-73 [2475911.001]

[Cites] Am J Physiol. 1999 Apr;276(4 Pt 1):C827-37 [10199813.001]

[Cites] J Membr Biol. 2004 Apr 1;198(3):113-24 [15216413.001]

[Cites] Science. 1995 Nov 17;270(5239):1166-70 [7502040.001]

[Cites] EMBO Rep. 2001 Nov;2(11):1047-51 [11606421.001]

[Cites] An Acad Bras Cienc. 2000 Sep;72(3):399-406 [11028104.001]

[Cites] J Gen Physiol. 2002 Jul;120(1):71-85 [12084777.001]

[Cites] EMBO J. 1982;1(8):945-51 [6329717.001]

[Cites] J Physiol. 1998 May 1;508 ( Pt 3):825-36 [9518736.001]

[Cites] Pflugers Arch. 2000 Jun;440(2):193-201 [10898518.001]

[Cites] Nat Struct Mol Biol. 2004 Oct;11(10):918-26 [15452563.001]

[Cites] Nat Rev Mol Cell Biol. 2002 Apr;3(4):256-66 [11994745.001]

[Cites] Nature. 1993 Feb 25;361(6414):682-3 [8441459.001]

[Cites] Pflugers Arch. 2001 Nov;443(2):202-11 [11713645.001]

[Cites] Pflugers Arch. 2003 Jan;445(4):504-12 [12548397.001]

[Cites] Cell Physiol Biochem. 2008;22(1-4):93-100 [18769035.001]

[Cites] EMBO J. 1998 Feb 16;17(4):898-908 [9463368.001]

[Cites] Physiol Rev. 2002 Apr;82(2):503-68 [11917096.001]

[Cites] Am J Physiol Renal Physiol. 2004 Oct;287(4):F722-31 [15161604.001]

[Cites] J Gen Physiol. 2003 Sep;122(3):333-48 [12939393.001]

[Cites] Physiol Rev. 1999 Oct;79(4):1317-72 [10508236.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):8083-8 [8755607.001]

[Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):G491-8 [9950824.001]

[Cites] Kidney Int. 2001 Aug;60(2):455-61 [11473626.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6832-6 [7542778.001]

[Cites] Curr Med Chem. 2006;13(7):771-82 [16611066.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9262-6 [1718002.001]

[Cites] Kidney Int. 2006 Feb;69(3):440-9 [16514429.001]

[Cites] Physiol Rev. 1985 Jul;65(3):760-97 [2409564.001]

[Cites] Nature. 2005 Feb 24;433(7028):876-80 [15729345.001]

[Cites] Am J Physiol. 1999 Dec;277(6 Pt 2):F826-31 [10600928.001]

[Cites] J Biol Chem. 1998 Feb 27;273(9):5235-42 [9478979.001]

[Cites] Respir Physiol. 1997 Feb;107(2):173-80 [9108631.001]

[Cites] Crit Rev Biochem Mol Biol. 2008 Jan-Feb;43(1):3-36 [18307107.001]

[Cites] Am J Physiol. 1996 Sep;271(3 Pt 2):F723-35 [8853436.001]

[Cites] Nature. 2000 Jan 13;403(6766):196-9 [10646604.001]

[Cites] Braz J Med Biol Res. 1999 Aug;32(8):1021-8 [10454765.001]

[Cites] Science. 1992 May 8;256(5058):774-9 [1375392.001]

[Cites] J Biol Chem. 1998 Jun 5;273(23):14165-71 [9603917.001]

[Cites] J Mol Biol. 1999 Oct 22;293(2):381-99 [10529352.001]

[Cites] Am J Physiol. 1996 Feb;270(2 Pt 1):C585-92 [8779923.001]

[Cites] Nature. 2006 Mar 23;440(7083):477-83 [16554808.001]

[Cites] Am J Physiol. 1992 Aug;263(2 Pt 1):C267-86 [1381146.001]

[Cites] Science. 1995 Aug 11;269(5225):847-50 [7543698.001]

[Cites] J Endocrinol. 2006 Apr;189(1):155-65 [16614390.001]

[Cites] Cell Physiol Biochem. 2007;20(5):455-64 [17762172.001]

[Cites] Annu Rev Physiol. 1993;55:609-30 [7682047.001]

[Cites] Cell. 1992 Feb 21;68(4):809-18 [1371239.001]

[Cites] J Membr Biol. 1999 Mar 1;168(1):1-8 [10051684.001]

[Cites] Physiol Rev. 2008 Apr;88(2):351-87 [18391167.001]

[Cites] Nature. 1993 Feb 25;361(6414):726-30 [8441467.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G663-70 [14630642.001]

[Cites] Purinergic Signal. 2008 Jun;4(2):125-37 [18368527.001]

[Cites] Ophthalmic Genet. 2003 Jun;24(2):75-80 [12789571.001]

[Cites] Science. 1995 Apr 21;268(5209):426-9 [7716548.001]

[Cites] Physiol Rev. 1999 Jan;79(1 Suppl):S145-66 [9922379.001]

[Cites] Cell. 1995 Jun 30;81(7):1063-73 [7541313.001]

[Cites] Am J Physiol. 1997 Nov;273(5 Pt 2):F843-8 [9374850.001]

[Cites] J Am Soc Nephrol. 2007 Mar;18(3):707-18 [17287432.001]

[Cites] Nature. 2001 Nov 29;414(6863):558-61 [11734858.001]

[Cites] J Physiol. 2000 Apr 1;524 Pt 1:77-90 [10747185.001]

[Cites] J Biol Chem. 2002 Jun 14;277(24):21111-4 [11964392.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2674-9 [9482946.001]

[Cites] Pflugers Arch. 2009 Apr;457(6):1227-36 [18839205.001]

[Cites] Physiol Rev. 1998 Jan;78(1):227-45 [9457174.001]

[Cites] J Bioenerg Biomembr. 2005 Dec;37(6):475-9 [16691486.001]

[Cites] Am J Physiol Renal Physiol. 2001 Jun;280(6):F945-63 [11352834.001]

[Cites] Annu Rev Physiol. 2005;67:701-18 [15709975.001]

[Cites] Jpn J Physiol. 1994;44 Suppl 2:S1-2 [7752510.001]

[Cites] Biol Pharm Bull. 1999 Oct;22(10):1027-33 [10549850.001]

[Cites] Nature. 1996 Sep 26;383(6598):340-3 [8848047.001]

[Cites] Jpn J Physiol. 1994;44 Suppl 2:S3-8 [7752544.001]

[Cites] FEBS Lett. 2006 Feb 13;580(4):1103-11 [16387301.001]

[Cites] Pflugers Arch. 2003 Jan;445(4):513-21 [12548398.001]

[Cites] Cell Physiol Biochem. 2007;20(1-4):83-90 [17595518.001]

[Cites] EMBO J. 2005 Jun 1;24(11):1901-10 [15889153.001]

[Cites] Structure. 2001 Jul 3;9(7):571-86 [11470432.001]

(PMID = 28510151.001).

[ISSN] 1867-2450

[Journal-full-title] Biophysical reviews

[ISO-abbreviation] Biophys Rev

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Germany

[Keywords] NOTNLM ; CFTR / Chloride channel / ENaC / Kidney / Nephron / ROMK / TNR-CFTR

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The May-Hegglin anomaly in a kidney transplant recipient.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Hematol. 1992 Jul;40(3):216-21 [1319112.001]

[Cites] Semin Thromb Hemost. 2009 Mar;35(2):189-203 [19408192.001]

[Cites] Am J Kidney Dis. 2009 Oct;54(4):732-40 [19726116.001]

[Cites] Saudi J Kidney Dis Transpl. 2009 Nov;20(6):1076-8 [19861875.001]

(PMID = 28657035.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; May–Hegglin anomaly / macrothrombocytes / renal failure / thrombocytopaenia

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A Kidney Exchange Clearinghouse in New England.

[MeSH-major] Kidney Transplantation. Tissue and Organ Procurement / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 29125723.001).

[ISSN] 0002-8282

[Journal-full-title] The American economic review

[ISO-abbreviation] Am Econ Rev

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

From 1989 to 1995 we conducted a series of simultaneous islet-kidney transplants in six uremic type 1 diabetic patients.

Two female patients with duration of diabetes of 27 and 37 years underwent simultaneous islet-kidney transplant under steroid- and cyclosporine-based immunosuppression.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28858603.001).

[ISSN] 1555-3892

[Journal-full-title] Cell transplantation

[ISO-abbreviation] Cell Transplant

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Immunosuppression / Islet transplantation / Long-term function / Simultaneous islet–kidney transplantation / Type 1 diabetes

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Renal ultrasound in acute kidney injury: long-term findings.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Kidney Dis. 2000 Jun;35(6):1021-38 [10845813.001]

[Cites] Kidney Int. 2007 Apr;71(7):679-86 [17264879.001]

[Cites] J Ultrasound Med. 1982 Mar;1(2):49-52 [6152926.001]

[Cites] Am J Kidney Dis. 1998 Oct;32(4):703 [9774138.001]

(PMID = 28657038.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI.

This narrative clinical review in two parts discusses the prevention of clinical acute kidney injury (AKI).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] JAMA. 2002 Aug 21;288(7):862-71 [12186604.001]

[Cites] Anesth Analg. 2008 Jun;106(6):1627-32 [18499589.001]

[Cites] Intensive Care Med. 2008 Apr;34(4):659-63 [18214429.001]

[Cites] Am J Nephrol. 2007;27(1):55-62 [17259694.001]

[Cites] Acta Clin Belg. 2007;62 Suppl 2:412-6 [18284012.001]

[Cites] Crit Care Med. 2006 May;34(5):1402-7 [16540963.001]

[Cites] Nephrol Dial Transplant. 2007 Nov;22(11):3097-101 [17617650.001]

[Cites] J Am Coll Cardiol. 2007 Mar 27;49(12):1283-8 [17394959.001]

[Cites] Kidney Int. 1997 Oct;52(4):886-94 [9328926.001]

[Cites] Curr Opin Crit Care. 2002 Dec;8(6):509-14 [12454534.001]

[Cites] Crit Care Med. 2008 Jan;36(1 Suppl):S75-88 [18158481.001]

[Cites] Crit Care. 2007;11(2):R31 [17331245.001]

[Cites] Br J Radiol. 1999 Jul;72 (859):701-3 [10624328.001]

[Cites] J Trauma. 2006 Sep;61(3):624-8 [16966998.001]

[Cites] N Engl J Med. 2006 Jun 15;354(24):2564-75 [16714767.001]

[Cites] J Clin Invest. 1983 Mar;71(3):726-35 [6826732.001]

[Cites] Circulation. 2007 Mar 13;115(10 ):1211-7 [17309916.001]

[Cites] JAMA. 2008 Aug 27;300(8):933-44 [18728267.001]

[Cites] J Am Soc Nephrol. 2007 Mar;18(3):860-7 [17301189.001]

[Cites] Clin J Am Soc Nephrol. 2008 Sep;3(5):1274-81 [18463172.001]

[Cites] Clin J Am Soc Nephrol. 2008 Jan;3(1):10-8 [18057306.001]

[Cites] J Am Soc Nephrol. 2008 Jul;19(7):1360-70 [18385426.001]

[Cites] Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000567 [17943746.001]

[Cites] BMJ. 2004 Aug 28;329(7464):480 [15289273.001]

[Cites] J Am Coll Cardiol. 2008 Aug 19;52(8):599-604 [18702961.001]

[Cites] Crit Care Med. 2004 Mar;32(3):691-9 [15090949.001]

[Cites] J Am Soc Nephrol. 2008 Jul;19(7):1253-5 [18508961.001]

[Cites] J Am Coll Cardiol. 1999 Feb;33(2):403-11 [9973020.001]

[Cites] Intensive Care Med. 2002 Apr;28(4):392-8 [11967591.001]

[Cites] Crit Care. 2008;12(1):R29 [18312617.001]

[Cites] Nephrol Dial Transplant. 2008 Apr;23 (4):1233-40 [18256017.001]

[Cites] Clin J Am Soc Nephrol. 2008 Sep;3(5):1266-73 [18667735.001]

[Cites] Crit Care Med. 2008 Aug;36(8):2316-21 [18596625.001]

[Cites] Curr Opin Nephrol Hypertens. 2006 May;15(3):285-90 [16609296.001]

[Cites] Arch Intern Med. 1979 Jul;139(7):801-5 [454069.001]

[Cites] Anesth Analg. 2005 May;100(5):1518-24, table of contents [15845718.001]

[Cites] Nephron Clin Pract. 2007;105(2):c77-83 [17143010.001]

[Cites] J Am Soc Nephrol. 2004 Jul;15(7):1862-7 [15213274.001]

[Cites] N Engl J Med. 2008 Jan 10;358(2):125-39 [18184958.001]

[Cites] JAMA. 2006 Jun 21;295(23):2765-79 [16788132.001]

[Cites] J Am Coll Cardiol. 2006 Aug 15;48(4):692-9 [16904536.001]

[Cites] J Am Coll Cardiol. 2007 Aug 14;50(7):584-90 [17692741.001]

[Cites] Clin J Am Soc Nephrol. 2007 Mar;2(2):356-65 [17699435.001]

[Cites] Arch Intern Med. 2008 Jun 23;168(12):1325-32 [18574090.001]

[Cites] Circulation. 2007 Jun 26;115(25):3189-96 [17562951.001]

[Cites] J Am Soc Nephrol. 2008 Mar;19(3):571-8 [18235100.001]

[Cites] N Engl J Med. 2003 Feb 6;348(6):491-9 [12571256.001]

[Cites] Nephron Clin Pract. 2003 Jan;93(1):C29-34 [12411756.001]

[Cites] Circulation. 2006 Apr 11;113(14):1799-806 [16606801.001]

[Cites] Ren Fail. 1997 Sep;19(5):647-53 [9380883.001]

[Cites] Crit Care Med. 2008 Apr;36(4 Suppl):S216-23 [18382197.001]

[Cites] Clin J Am Soc Nephrol. 2008 May;3(3):864-8 [18287251.001]

[Cites] Kidney Int. 2003 Feb;63(2):600-6 [12631124.001]

[Cites] N Engl J Med. 2006 May 25;354(21):2213-24 [16714768.001]

[Cites] Coron Artery Dis. 2008 Sep;19(6):413-9 [18955835.001]

[Cites] Crit Care Med. 2004 Mar;32(3):858-73 [15090974.001]

[Cites] Invest Radiol. 2006 Nov;41(11):815-21 [17035872.001]

[Cites] Acta Clin Belg. 2007;62 Suppl 2:346-52 [18283997.001]

[Cites] Ann Med. 2005;37(1):13-25 [15902843.001]

[Cites] J Trauma. 1994 Aug;37(2):214-9 [8064919.001]

[Cites] Anesth Analg. 2001 Oct;93(4):817-22 [11574339.001]

[Cites] N Engl J Med. 1995 Oct 19;333(16):1025-32 [7675044.001]

[Cites] Chest. 2008 Jan;133(1):252-63 [18187750.001]

[Cites] Semin Respir Crit Care Med. 2007 Dec;28(6):596-603 [18095223.001]

[Cites] J Am Coll Cardiol. 2008 Apr 15;51(15):1419-28 [18402894.001]

[Cites] N Engl J Med. 2001 Nov 8;345(19):1359-67 [11794168.001]

[Cites] J Am Coll Cardiol. 2008 Jan 1;51(1):89-90 [18174044.001]

[Cites] Med Mycol. 2008 Mar;46(2):97-112 [18324488.001]

[Cites] N Engl J Med. 2006 Feb 2;354(5):449-61 [16452557.001]

[Cites] N Engl J Med. 1994 Nov 24;331(21):1416-20 [7969280.001]

[Cites] Chest. 2007 Jan;131(1):300-8 [17218591.001]

[Cites] Kidney Int. 1996 Feb;49(2):314-26 [8821813.001]

[Cites] Clin J Am Soc Nephrol. 2008 Jul;3(4):962-7 [18354074.001]

[Cites] N Engl J Med. 2001 Nov 8;345(19):1368-77 [11794169.001]

[Cites] Best Pract Res Clin Anaesthesiol. 2008 Mar;22(1):135-49 [18494393.001]

[Cites] Shock. 2006 Dec;26(6):551-7 [17117128.001]

[Cites] Arch Intern Med. 2002 Feb 11;162(3):329-36 [11822926.001]

[Cites] Clin J Am Soc Nephrol. 2008 Jan;3(1):273-80 [17989201.001]

[Cites] Mil Med. 1999 May;164(5):366-9 [10332179.001]

[Cites] Best Pract Res Clin Anaesthesiol. 2004 Mar;18(1):37-52 [14760873.001]

[Cites] N Engl J Med. 2008 Jan 10;358(2):111-24 [18184957.001]

[Cites] CMAJ. 2005 Oct 25;173(9):1054-65 [16247103.001]

[Cites] N Engl J Med. 2004 May 27;350(22):2247-56 [15163774.001]

[Cites] J Am Soc Nephrol. 2000 Aug;11(8):1553-61 [10906171.001]

[Cites] N Engl J Med. 2006 Mar 9;354(10):1052-63 [16525142.001]

[Cites] Chest. 2005 Aug;128(2):848-54 [16100177.001]

[Cites] Chest. 1998 Dec;114(6):1570-4 [9872190.001]

[Cites] Crit Care Med. 2008 Jun;36(6):1937-49 [18496365.001]

[Cites] Nephrol Dial Transplant. 2007 Oct;22(10):2849-55 [17604310.001]

[Cites] Ann Intern Med. 2008 Feb 19;148(4):284-94 [18283206.001]

[Cites] Nephrol Dial Transplant. 2006 Jun;21(6):i11-23 [16723348.001]

[Cites] JAMA. 2004 May 19;291(19):2328-34 [15150204.001]

[Cites] Crit Care Med. 2007 Dec;35(12):2740-6 [17893629.001]

[Cites] Chest. 2005 Oct;128(4):1902-3 [16236833.001]

[Cites] Acta Clin Belg. 2007;62 Suppl 2:408-11 [18284011.001]

[Cites] J Nephrol. 2005 Jan-Feb;18(1):54-60 [15772923.001]

[Cites] Clin Infect Dis. 2001 Mar 1;32(5):686-93 [11229835.001]

[Cites] N Engl J Med. 2006 Oct 19;355(16):1699-713 [17050894.001]

[Cites] Am Heart J. 2004 Feb;147(2):331-8 [14760333.001]

[Cites] J Am Coll Cardiol. 2006 Sep 5;48(5):924-30 [16949481.001]

[Cites] JAMA. 2008 Aug 27;300(8):963-5 [18728273.001]

[Cites] Kidney Int. 2008 Feb;73(4):379-81 [18235520.001]

[Cites] Semin Dial. 2007 May-Jun;20(3):179-85 [17555477.001]

[Cites] Int J Artif Organs. 2008 Feb;31(2):111-26 [18311728.001]

[Cites] Int J Artif Organs. 2008 Feb;31(2):94-5 [18311726.001]

[Cites] Int J Artif Organs. 2008 Feb;31(2):96-110 [18311727.001]

(PMID = 28657002.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Editorial

[Publication-country] England

[Keywords] NOTNLM ; acute kidney injury / fluid therapy / prevention / tight glycaemia control / volume expansion

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Renal resistance index-think of more than just the kidney.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Transplant. 2006 Nov;6(11):2721-4 [17049059.001]

[Cites] Ann Thorac Surg. 2009 Nov;88(5):1484-91 [19853098.001]

[Cites] NDT Plus. 2009 Dec;2(6):495-7 [25949389.001]

(PMID = 28657064.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; kidney transplantation / resistance index / vascular graft

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sci-Sat AM(1): Imaging-01: Tumour and normal tissue T2 and ADC distributions for a mouse model at 9.4T.

We are currently using mouse models of human glioblastoma multiforme (GBM) to study tumour response to ionizing radiation by MRI at 9.4T.

Utilizing conventional imaging techniques coupled with quantitative measurements of transverse relaxation time (T2) and apparent diffusion coefficient (ADC), we monitor changes during tumour growth and subsequent changes after single-fraction radiotherapy.

In addition to tumour parameters, we have measured T2 and ADC in other structures that appear in the same transverse slices as tumour tissue.

Here we report the measured distributions of T2 and ADC in tumour and in normal tissues that are likely to be encountered during MR imaging of tumour xenografts in mice, including liver, kidney, fat, skeletal muscle, spinal cord, and brain.

Knowledge of parameter distributions in tumour is important because recent studies have suggested that the T2 and ADC responses after therapy may be the result of large shifts in smaller isolated pockets of tumour, rather than more moderate shifts in T2 and ADC over the whole tumour volume.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2008 American Association of Physicists in Medicine.

(PMID = 28512910.001).

[ISSN] 2473-4209

[Journal-full-title] Medical physics

[ISO-abbreviation] Med Phys

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Cancer / Diffusion / Ionizing radiation / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Radiation therapy / Relaxation times / Time measurement / Tissues

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

To establish if the isolated hepatocytes could be used as a source for cell-based therapies, we transplanted the Ad-transduced hepatocytes into the liver or under the kidney capsule.

We also confirmed that these Ad-transduced hepatocytes have ability to survive long term and were able to engineer a biologically active hepatic tissue under the kidney capsule.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28871876.001).

[ISSN] 1555-3892

[Journal-full-title] Cell transplantation

[ISO-abbreviation] Cell Transplant

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Adenoviral vector / Ex vivo gene therapy / Gene modification / Hepatocyte transplantation / Liver tissue engineering

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Renal Medullary Carcinoma is a Diagnosis Worth Considering: Case Report.

Medullary Renal Carcinoma is a rare, highly malignant neoplasm that originates in the renal medulla and typically affects young black patients with sickle cell trait.

We report the case of a 17-year-old boy with a symptomatic left renal tumour.

CT revealed that the mass originated from the kidney and was associated with a large para-aortic lymph node mass.

Hemoglobin electrophoresis showed sickle cell trait and a needle biopsy confirmed the diagnosis of Renal Medullary Carcinoma.

We discuss the obscurity and implications of such a diagnosis.

It is essential that clinicians are aware of this diagnosis as any delay can be fatal in the outcome of this highly aggressive and extremely rare cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Surg Pathol. 1995 Jan;19(1):1-11 [7528470.001]

[Cites] Pediatr Pathol Lab Med. 1998 Jan-Feb;18(1):97-113 [9566287.001]

[Cites] Urology. 2007 Nov;70(5):878-82 [18068443.001]

[Cites] Kidney Int. 2000 Jan;57(1):1-8 [10620181.001]

[Cites] AJR Am J Roentgenol. 2005 Jul;185(1):268-72 [15972435.001]

[Cites] Urology. 2002 Dec;60(6):1083-9 [12475675.001]

[Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]

(PMID = 29147202.001).

[ISSN] 1920-454X

[Journal-full-title] World journal of oncology

[ISO-abbreviation] World J Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Keywords] NOTNLM ; Medullary cell cancer / sickle cell

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Use of cystatin C as a marker to detect renal insufficiency in head and neck cancer patients with cisplatin-based chemotherapy.

: e17048 Background: Knowledge of the usefulness of cystatin C measurement in the detection of chronic kidney disease in patients with head and neck cancer (HNC) is scant.

The purpose of this study was to evaluate the ability of plasma cystatin C- and creatinine-based methods to predict glomerular filtration rate (GFR) and classify chronic kidney disease in HNC patients before receiving cisplatin based chemotherapy.

Comparisons were made between measured plasma creatinine, cystatin C, creatinine clearance and GFR estimated by the Modification of Diet in Renal Disease (MDRD) formula.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961772.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Immunohistochemistry suggested the most likely diagnosis was that of metastatic carcinoma with a number of potential primary sites.

Computed tomography scanning showed widespread metastatic disease, including lung, liver, kidney, omentum, subcutaneous and intramuscular lesions.

Primary cancers that most commonly metastasise to soft tissues include those arising within the lung, colon and kidney.

The most frequent histological diagnosis is adenocarcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]

[Cites] Clin Orthop Relat Res. 1993 Nov;(296):213-7 [8222429.001]

[Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]

[Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]

[Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]

[Cites] J Clin Oncol. 2007 Aug 20;25(24):3780-3 [17704428.001]

[Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]

[Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]

[Cites] Ann Thorac Surg. 1996 May;61(5):1525-6 [8633975.001]

(PMID = 29147193.001).

[ISSN] 1920-454X

[Journal-full-title] World journal of oncology

[ISO-abbreviation] World J Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Keywords] NOTNLM ; Biopsy / Esophagus / Occult cancer / Soft tissue metastasis / Squamous cell carcinoma

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Global Expression Profiles in 1-Hour Biopsy Specimens of Human Kidney Transplantation from Donors after Cardiac Death.

Because of the worldwide shortage of renal grafts, kidney transplantation (KTx) from donors after cardiac death (DCD) is an alternative way to obtain KTx from brain-dead donors.

In an attempt to characterize etiology of DGF, genome-wide gene expression profiling was performed using renal biopsy samples performed at 1 h after KTx from DCD and the data were compared with those of KTx from living donors (LD).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28880652.001).

[ISSN] 1555-3892

[Journal-full-title] Cell transplantation

[ISO-abbreviation] Cell Transplant

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Delayed graft function / Donation after cardiac death / Gene expression / Kidney transplantation

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence of acute kidney injury in cancer patients: A population-based cohort study in Denmark.

: 9570 Background: Although cancer patients may be at increased risk for acute kidney injury (AKI), which could then reduce their likelihood of receiving optimal therapeutic management and supportive care, the occurrence of AKI among newly diagnosed cancer patients has not been well-described.

Therefore, we examined the incidence of AKI within the first year after cancer diagnosis to estimate the magnitude of this risk and better understand which patients are at greatest risk.

AKI was defined according to the Risk/ Injury/ Failure/ Loss/ End-stage-renal-disease (RIFLE) criteria.

Baseline sCr was defined as the lowest sCr in the year before cancer diagnosis.

We compared this value to the highest sCr on record during the first year following cancer diagnosis to identify those who experienced an AKI.

Incidence was highest among patients aged 80 years or older (531 per 1,000 person-years, 95% CI 464-606) and in those with cancer of the liver (1,221, 95%CI 676-2,205), pancreas (1,472, 95%CI 1,130-1,917), or kidney (1,254, 95%CI 974-1,616), or with multiple myeloma (855, 95%CI 538-1,356).

Our study showed that over 20% of cancer patients may experience acute kidney injury in the first year after diagnosis.

Older patients and those with cancer of the liver, pancreas, or kidney, or with multiple myeloma are especially at risk for AKI.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963659.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI).

There are limited data on the clinical toxicity profile and efficacy of these agents in pts with RI.

METHODS: The primary objective was to assess the safety and efficacy of S, B, T and E in pts with RI.

Pts with a calculated creatinine clearance (CrCl) of ≤ 60ml/min [chronic kidney disease stage 3 or higher per K/DOQI guidelines by the National Kidney Foundation] were deemed to have RI.

Data on safety and efficacy of the therapy were collected and analyzed with respect to renal function.

RESULTS: 19 of 51 (37%) pts had RI.

Pts with RI had a higher median rise in blood pressure (BP) with S and B than pts with normal renal function.

Patients with RI had an increased incidence of rash and higher dose interruption rates with m-TOR inhibitors.

No major differences in toxicities including cardiac, thyroid, renal, lipid profile abnormalities or hyperglycemia were observed.

CONCLUSIONS: More than a third of pts with mRCC receiving targeted therapy have RI, hence highlighting the importance of evaluating tolerability of therapies in pts with RI.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964365.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients.

: 10567 Background: The objective of this study is to investigate the characteristics and survival rate of patients with Gastrointestinal Stromal Tumor (GIST) associated with other primary malignancies.

Multiple primaries included tumors that were not considered to be a metastasis, invasion or recurrence of GIST excluding non-melanoma skin cancer.

Data on gender, age at diagnosis of cancer, follow-up time after diagnosis, and death rate were collected.

Median age at diagnosis of GIST was 57 for patients with GIST only whereas it was 68 in patients with GIST+.

The total numbers of other primaries developed before the diagnosis of GIST was higher (134) than the primaries developed after the diagnosis of GIST (53).

The most frequent primaries observed before the diagnosis of GIST were prostate (25), breast (12), esophagus (9), kidney (7) and melanoma (6).

Lung (5) and kidney (5) were the most frequent type of primaries that developed after the diagnosis of GIST.

The 5-yr survival was 68% for patients with GIST+ when the other primary occurred before GIST, 61% for patients with GIST+ when the other primary occurred after the diagnosis of GIST, 58% for patients with GIST only, and 49% for GIST++ patients with two or more other primaries (p=0.002).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963788.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sunitinib, sorafenib, temsirolimus, or bevacizumab in the treatment of metastatic renal cell carcinoma (RCC): A review of health economic evaluations.

: e17539 Background: Renal cell carcinoma (RCC) is the most prevalent kidney cancer and the 5-year overall survival figure in metastatic disease (mRCC) is about 10%.

The PubMed, ASCO abstracts, Google, and the Igaku Chuo Zasshi databases were searched in November 2008 with key terms: kidney, renal, cancer, cost, sunitinib, sorafenib, temsirolimus, and bevacizumab.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963791.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients.

: e17516 Background: Patient-reported outcomes (PRO), including health-related quality of life (HRQL), were assessed in a Phase III trial of everolimus in metastatic renal cell carcinoma (mRCC) patients.

Patients completed the FACT-Kidney Symptom Index- Disease Related Symptoms (FKSI-DRS) and EORTC-QLQ C30 at baseline and monthly during treatment.

Secondary analyses considered tumor progressions that occurred prior to deterioration or censoring date as FKSI deterioration events and compared time to PRO deterioration by tumor progression.

Secondary analyses suggest a delay in deterioration in kidney cancer related symptoms via tumor control.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963270.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

To learn more about nonimmune-mediated islet graft failure, we transplanted different preparations (preps) of isolated human islets under the kidney capsule of streptozotocin (STZ)-diabetic nude mice.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28876095.001).

[ISSN] 1555-3892

[Journal-full-title] Cell transplantation

[ISO-abbreviation] Cell Transplant

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Athymic nude mice / Islet transplantation / Prohormone convertase 2 (PC2) / Proinsulin processing / p16INK4 / p21WAF1 / p27Kip1

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

EXPERIMENTAL DESIGN: Eligibility: Main inclusion criteria: Stage IV or stage IIIB NSCLC; Eastern Cooperative Oncology Group(ECOG) performance status (PS) 0-1; Measurable disease; Adequate bone marrow, kidney, liver function.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962246.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Although lineage specific hematopoietic growth factors play important roles in the treatment of cancer and chronic kidney disease, recent basic and clinical research studies have identified toxicities.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962008.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

EMR presented 60 to 1010 days after the allograft and appeared in 3 cases as subcutaneous nodules in different parts of the body, in the vertebrae in 3 cases, and in the kidney and the breast in 1 case each.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28401517.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Japan

[Keywords] NOTNLM ; Allograft / Extramedullary / Leukemia / Nonmyeloablative / Relapse

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The antitumor activity of KD3-IFN was significantly higher than that of a control vector in established human hepatocellular carcinoma tumors in immunodeficient mice and in hamster kidney cancer tumors in immunocompetent Syrian hamsters.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.

(PMID = 28182898.001).

[ISSN] 1525-0024

[Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy

[ISO-abbreviation] Mol. Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

GB1201 significantly inhibited the rat Tgf-β1 gene promoter activity in HEK (human embryonic kidney) 293 cells in a concentration-dependent manner.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.

(PMID = 28182879.001).

[ISSN] 1525-0024

[Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy

[ISO-abbreviation] Mol. Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

After i.v. administration, the oligonucleotide peak levels in plasma, liver, and kidney were higher than after s.c. or i.p. injections.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.

(PMID = 28178497.001).

[ISSN] 1525-0024

[Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy

[ISO-abbreviation] Mol. Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chronic kidney disease:risk factors, assessment and nursing care.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27959131.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; Chronic illness / Chronic renal failure / Kidney disease / Nursing care

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In the liver and spleen of animals treated with 10 nm gold nanoparticles, groups of nanoparticles were observed that could be positively identified by Energy Dispersive X-ray (EDX) analysis to contain gold, while nanoparticles could not be detected in the heart, kidney and brain.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Angew Chem Int Ed Engl. 2007;46(30):5754-6 [17591736.001]

[Cites] Environ Health Perspect. 2005 Nov;113(11):1555-60 [16263511.001]

[Cites] Environ Sci Technol. 2006 Jul 15;40(14):4353-9 [16903270.001]

[Cites] Biomaterials. 2008 Apr;29(12):1912-9 [18242692.001]

[Cites] J Control Release. 2009 Oct 1;139(1):81-4 [19538994.001]

[Cites] Part Fibre Toxicol. 2007 Oct 19;4:10 [17949501.001]

[Cites] Nanomedicine. 2009 Jun;5(2):162-9 [19217434.001]

[Cites] J Pharm Sci. 1995 Apr;84(4):493-8 [7629743.001]

[Cites] Biomaterials. 1999 Jul;20(14):1269-75 [10403044.001]

[Cites] J Control Release. 2006 Sep 12;114(3):343-7 [16876898.001]

(PMID = 28883347.001).

[ISSN] 1996-1944

[Journal-full-title] Materials (Basel, Switzerland)

[ISO-abbreviation] Materials (Basel)

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

[Keywords] NOTNLM ; gold nanoparticles / tissue distribution / transmission electron microscopy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We cotransplanted 500 BALB/c islets with 1-8 million BALB/c SC under the kidney capsule of diabetic BALB/c, C3H-HeJ, and C57BL/6 mice.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28866926.001).

[ISSN] 1555-3892

[Journal-full-title] Cell transplantation

[ISO-abbreviation] Cell Transplant

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Diabetes / Islet / Sertoli cell / Transplantation

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Calcium Kinetic in a patient with acute renal failure due to Rhabdomyolysis. A Case Report and Review of Literature.

Hypercalcemia may follow hypocalcemia in the course of acute renal failure (also named now as acute kidney injury) secondary to rhabdomyolysis.

The patient was discharged 3 weeks after admission with a recovered clinical condition, improved renal functions and normal calcemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Crit Care. 2007;11(2):R31 [17331245.001]

[Cites] Clin Nephrol. 1993 Jan;39(1):22-7 [8428403.001]

[Cites] Crit Care. 2005 Apr;9(2):158-69 [15774072.001]

[Cites] J Clin Endocrinol Metab. 1986 Jul;63(1):137-42 [3011837.001]

[Cites] Am J Kidney Dis. 2004 Mar;43(3):e31-5 [14981639.001]

[Cites] Br Med J. 1941 Mar 22;1(4185):427-32 [20783577.001]

[Cites] N Engl J Med. 1981 Jul 16;305(3):117-23 [6894630.001]

[Cites] J Am Soc Nephrol. 2000 Aug;11(8):1553-61 [10906171.001]

(PMID = 28845216.001).

[ISSN] 1999-768X

[Journal-full-title] Oman medical journal

[ISO-abbreviation] Oman Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] Oman

[Keywords] NOTNLM ; Acute kidney injury / Hypercalcemia / Hypocalcemia / Rhabdomyolysis

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e22168 Background: CUP are an heterogeneous family of neoplasms with a dismal prognosis, with empiric chemotherapy as the recommended treatment.

Gene expression profiling was performed using oligonucleotide microarray that contains 495 genes selected as highly differentially expressed between 49 tumor types (CupPrint).

Of note, a primary cancer which would not be adequately treated by an empiric chemotherapy regimen currently recommended in CUP (like cisplatin-gemcitabine or carboplatin-paclitaxel) was identified in about half patients: kidney cancer (1), hepatocarcinoma (1), colorectal cancer (3), head and neck cancer (2) and cholangiocarcinoma (1).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963676.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Central venous catheter-related right atrial thrombus in two kidney transplantation recipients.

There is an increased risk of thromboembolism following renal transplantation.

However, a right atrial thrombosis is rarely reported in renal transplant recipients.

Here, we report two cases of renal transplant recipients in whom a right atrial thrombus developed after kidney transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pediatr Transplant. 2008 Mar;12(2):251-5 [18179641.001]

[Cites] Angiology. 2001 Jun;52(6):425-8 [11437034.001]

[Cites] Am Heart J. 1998 Mar;135(3):457-62 [9506332.001]

[Cites] Intensive Care Med. 2003 Oct;29(10):1829-32 [12897992.001]

[Cites] J Pediatr. 1982 Jan;100(1):149-52 [6799632.001]

[Cites] South Med J. 2008 Jun;101(6):662-3 [18528224.001]

[Cites] Saudi J Kidney Dis Transpl. 2008 Jan;19(1):90-3 [18087132.001]

[Cites] Cancer. 1992 Oct 1;70(7):1895-8 [1326397.001]

[Cites] Eur Heart J. 1993 Jan;14 (1):138-40 [8432282.001]

[Cites] Surg Gynecol Obstet. 1979 Jun;148(6):871-5 [109934.001]

(PMID = 28657063.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; anticoagulant therapy / central venous catheter / kidney transplantation / right atrial thrombus / surgery treatment

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficient Kidney Exchange: Coincidence of Wants in Markets with Compatibility-Based Preferences.

Patients needing kidney transplants may have donors who cannot donate to them because of blood or tissue incompatibility.

Incompatible patient-donor pairs can exchange donor kidneys with other pairs only when there is a "double coincidence of wants."

[MeSH-minor] Humans. Kidney Transplantation. Models, Theoretical

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 29135211.001).

[ISSN] 0002-8282

[Journal-full-title] The American economic review

[ISO-abbreviation] Am Econ Rev

[Language] eng

[Grant] International / National Science Founcation / / SES-0616470; International / National Science Foundation / / SES-0616689

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: Lower haemoglobin, higher serum uric acid level, self-reported history of nocturia and family history of kidney disease are independent risk factors for end-stage renal disease (ESRD).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28001668.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: The Kidney Patient Guide website is a collaboration between healthcare professionals, writers, multimedia experts and, most importantly, renal failure patients and their families and carers.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28034125.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: We conducted a retrospective review of outpatient medical records of 2498 patients with metastatic solid tumors seen at an academic cancer center from 10/1/06 through 2/29/08.

The sample consisted of patients with metastatic breast, colorectal, non-colorectal gastrointestinal (GI), bladder/kidney, ovarian, prostate, and lung cancers.

Code status was documented more frequently in patients with metastatic non-colorectal GI (193/609, 31.7%) and lung (179/583, 30.7%) cancers compared to patients with genitourinary malignancies (bladder/kidney [4/89, 4.5%], ovarian [4/93, 4.3%] and prostate [7/365, 1.9%] cancers).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963711.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers.

: e14575 Background: Tumoral Gastrin-releasing peptide (GRP) receptors are potential targets for diagnosis and therapy using radiolabeled or cytotoxic GRP analogs.

GRP-receptor overexpression has been detected in cancer cells and, more recently, also in the vascular bed of selected tumors.

METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the ¹²⁵I-[Tyr⁴]-bombesin radioligand and/or the universal radioligand ¹²⁵I-[D-Tyr⁶, ß-Ala¹¹, Phe¹³, Nle¹⁴]-bombesin(6-14).

GRP-receptor expressing tumoral vessels were evaluated in each tumor group for prevalence, quantity (vascular score) and GRP-receptor density.

Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).

Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.

CONCLUSIONS: Tumoral vessels in all evaluated sites overexpress GRP-receptors, suggesting a major biological function of GRP-receptors in the tumor vascular bed.

Vascular GRP-receptor expression varies between the tumor-types indicating tumor-specific mechanisms in their regulation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963648.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: The gloriously named David Kidney, Labour MP for Stafford, has been doing his best to get a private member's bill through parliament to protect a woman's right to breastfeed in public.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27986015.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapeutic care in metastatic renal cell carcinoma during the follow-up phase of the RECORD-1 phase III trial.

: e17531 Background: Following drug discontinuation for progression or adverse event in a clinical trial for relapsed or stage IV kidney cancer, supportive care including surgery, palliative radiotherapy, or bisphosphonates continue to be recommended by National Comprehensive Cancer Network (NCCN).

METHODS: World Health Organization Anatomical Therapeutic Chemical codes or therapeutic names, captured from the follow-up phase in a phase III clinical trial (RECORD-1) of patients with metastatic renal cell carcinoma (mRCC) patients, were used to describe antineoplastic therapies following discontinuation of study drug.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963810.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Among the 757 individuals with available disease site and enrollment information, those with stomach cancer accounted for the most enrollments (25, 24.75% of all enrollments); followed by melanoma (12, 11.88%) and kidney, renal pelvis, bladder, ureter and urethra (also 12, 11.88%), and breast cancer (11, 10.89%).

Strategies for eliminating racial disparities, facilitating transportation, and increasing participation among patients with earlier stage disease and more common tumor types must be developed and implemented.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963240.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The remaining 127 (33%) had ovarian, lung, colorectal, prostate, bladder, kidney, or other malignancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961687.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Kidney stones can develop in children after antibiotics.

: Children taking the antibiotic ceftriaxone for a seven-day course may develop renal stones, Turkish researchers have found.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28006511.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In the gastric case, the coplanar 5-opt plan reduced the right kidney V 20 Gy by 41.1%, 32.1%, and 29.5% compared to the 5-equi, 7-equi, and 9-equi plans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2008 American Association of Physicists in Medicine.

(PMID = 28512894.001).

[ISSN] 2473-4209

[Journal-full-title] Medical physics

[ISO-abbreviation] Med Phys

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Annealing / Cancer / Dosimetry / Intensity modulated radiation therapy / Kidneys / Radiation therapy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chronic kidney disease and end-stage renal disease-a review produced to contribute to the report 'the status of health in the European union: towards a healthier Europe'.

Chronic kidney disease (CKD) is increasingly recognized as a major public health problem.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Intern Med. 2004 Jul 20;141(2):95-101 [15262664.001]

[Cites] JAMA. 2004 Jun 2;291(21):2616-22 [15173153.001]

[Cites] Kidney Int. 2006 Jul;70(1):26-33 [16723985.001]

[Cites] Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 [11904577.001]

[Cites] Nephrol Dial Transplant. 2005 Sep;20(9):1799-807 [15928100.001]

[Cites] Kidney Int. 2006 Aug;70(4):800-6 [16820784.001]

[Cites] Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201 [14520607.001]

[Cites] J Gen Intern Med. 2007 Jul;22(7):1018-23 [17436030.001]

[Cites] J Am Soc Nephrol. 2006 Aug;17(8):2275-84 [16790511.001]

[Cites] Kidney Int. 2005 Dec;68(6):2837-45 [16316361.001]

[Cites] Semin Nephrol. 2002 Nov;22(6):441-8 [12430088.001]

[Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]

[Cites] J Am Soc Nephrol. 2003 Oct;14(10):2573-80 [14514734.001]

[Cites] Kidney Int Suppl. 2005 Dec;(99):S16-9 [16336570.001]

[Cites] Nephrol Dial Transplant. 2001 Jun;16(6):1120-9 [11390709.001]

[Cites] Pediatr Nephrol. 2006 Mar;21(3):394-9 [16382317.001]

[Cites] Nephrol Dial Transplant. 2003 Sep;18(9):1824-33 [12937231.001]

[Cites] BMJ. 2006 Nov 18;333(7577):1047 [17062598.001]

[Cites] Hypertension. 2003 Nov;42(5):1050-65 [14604997.001]

[Cites] Ann Epidemiol. 2007 Jan;17(1):19-26 [17140811.001]

[Cites] Pediatr Nephrol. 2007 Dec;22(12):1999-2009 [17310363.001]

[Cites] Bull World Health Organ. 2008 Mar;86(3):229-37 [18368211.001]

[Cites] Pediatr Nephrol. 2004 Feb;19(2):213-21 [14685843.001]

[Cites] J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S131-8 [12819318.001]

[Cites] Circulation. 2002 Aug 6;106(6):703-10 [12163431.001]

[Cites] Kidney Int Suppl. 2004 Nov;(92):S7-10 [15485425.001]

[Cites] Kidney Int. 2007 Jul;72 (1):92-9 [17440495.001]

[Cites] Nephrol Dial Transplant. 2006 Aug;21(8):2178-83 [16595584.001]

[Cites] Nephrol Dial Transplant. 2001;16 Suppl 7:57-60 [11590259.001]

[Cites] Blood Purif. 2007;25(3):219-20 [17384501.001]

[Cites] J Am Soc Nephrol. 2002 Jan;13 Suppl 1:S37-40 [11792760.001]

[Cites] PLoS Med. 2004 Oct;1(1):e27 [15526049.001]

[Cites] Kidney Int. 2005 Apr;67(4):1489-99 [15780102.001]

[Cites] Int J Health Care Finance Econ. 2007 Sep;7(2-3):201-15 [17641969.001]

[Cites] J Am Soc Nephrol. 2005 Jan;16(1):180-8 [15563563.001]

[Cites] J Am Soc Nephrol. 2004 May;15(5):1300-6 [15100370.001]

[Cites] Kidney Int Suppl. 2005 Sep;(98):S25-9 [16108967.001]

[Cites] Eur Heart J. 2006 May;27(10):1245-50 [16611670.001]

[Cites] Nephrol Dial Transplant. 2007 Mar;22(3):678-80 [17314211.001]

[Cites] J Am Soc Nephrol. 2005 Jul;16(7):2134-40 [15901764.001]

[Cites] Clin Ther. 2006 Mar;28(3):432-44 [16750458.001]

[Cites] J Am Soc Nephrol. 2006 Jul;17(7):2034-47 [16738019.001]

[Cites] Pediatr Nephrol. 1997 Aug;11(4):438-42 [9260241.001]

[Cites] N Engl J Med. 2004 Sep 23;351(13):1296-305 [15385656.001]

[Cites] Pediatrics. 2003 Apr;111(4 Pt 1):e382-7 [12671156.001]

[Cites] Kidney Int. 2007 Jan;71(1):53-9 [17091125.001]

[Cites] Lancet. 2000 Jul 8;356(9224):147-52 [10963260.001]

[Cites] Am J Clin Nutr. 2006 Oct;84(4):707-16 [17023695.001]

[Cites] Nephrol Dial Transplant. 2006 Jul;21(7):1899-905 [16611686.001]

[Cites] Eur Heart J. 2007 Feb;28(4):478-83 [17223665.001]

[Cites] Am J Kidney Dis. 2004 May;43(5 Suppl 1):S1-290 [15114537.001]

[Cites] Am J Kidney Dis. 2005 Aug;46(2):225-32 [16112040.001]

[Cites] JAMA. 2003 May 21;289(19):2560-72 [12748199.001]

[Cites] Semin Nephrol. 2006 Jan;26(1):68-79 [16412831.001]

[Cites] Kidney Int. 2005 Dec;68(6):2801-8 [16316356.001]

[Cites] Kidney Int Suppl. 2005 Apr;(94):S28-35 [15752236.001]

[Cites] JAMA. 2003 Dec 17;290(23):3101-14 [14679273.001]

[Cites] J Am Soc Nephrol. 2006 Jun;17(6):1695-702 [16641153.001]

(PMID = 28657040.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; CKD / ESRD / epidemiology / public health

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Functional analyses using LN229, U87, and U118 glioblastoma cells, and human embryonic kidney 293T cells with transgene phenotypes for IκBα.

Functional analyses uncover a bona fide tumor suppressor role for IκBα in glioblastoma cells, where it functions to constrain tumorigenic and migratory potential, and induce spontaneous cellular senescence, and apoptosis in response to treatment.

Glioblastomas with initially high IκBα expression significantly repress IκBα upon tumor recurrence, suggesting an acquired mechanism to evade its tumor-suppressive and/or chemo-sensitizing effects during tumor progression.

CONCLUSIONS: IκBα is a molecular determinant of biological tumor behavior and patient survival in glioblastoma multiforme.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964596.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

No patient was found to have heart or kidney problem before the commencement of chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964095.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The Regenerative Potential of Stem Cells in Acute Renal Failure.

Little is known regarding the presence of stem cells in the adult kidney but it is documented that under certain conditions, such as the recovery from acute injury, the kidney can regenerate itself by increasing the proliferation of some resident cells.

The origin of these cells is largely undefined; they are often considered to derive from resident renal stem or progenitor cells.

Moreover, the contribution of bone marrow-derived stem cells to renal cell turnover and regeneration has been suggested.

Recent studies have demonstrated that hematopoietic stem cells were mobilized following ischemia/reperfusion and engrafted the kidney to differentiate into tubular epithelium in the areas of damage.

The evidence that mesenchymal stem cells, by virtue of their renoprotective property, restore renal tubular structure and also ameliorate renal function during experimental acute renal failure provides opportunities for therapeutic intervention.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28863770.001).

[ISSN] 1555-3892

[Journal-full-title] Cell transplantation

[ISO-abbreviation] Cell Transplant

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Acute renal failure / Kidney repair / Stem cells / Tubular cells

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The impact of end-stage kidney disease (ESKD) on close persons: a literature review.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nephrol Nurs J. 2005 Nov-Dec;32(6):621-31 [16425810.001]

[Cites] Nephrol Dial Transplant. 2007 Aug;22 Suppl 7:vii155-64 [17724043.001]

[Cites] Nephrol Dial Transplant. 2004 Jun;19(6):1357-60 [15004252.001]

[Cites] Am J Kidney Dis. 2006 Jan;47(1):122-30 [16377393.001]

[Cites] Perit Dial Int. 2003 Dec;23 Suppl 2:S200-5 [17986549.001]

[Cites] Am J Kidney Dis. 2002 Apr;39(4):805-12 [11920347.001]

[Cites] J Adv Nurs. 2000 Jun;31(6):1398-408 [10849152.001]

[Cites] EDTNA ERCA J. 1999 Apr-Jun;25(2):45-8 [10531884.001]

[Cites] Br J Psychiatry. 2007 Feb;190:142-7 [17267931.001]

[Cites] Am J Kidney Dis. 2006 Dec;48(6):955-63 [17162150.001]

[Cites] Gerontologist. 1980 Dec;20(6):649-55 [7203086.001]

[Cites] ANNA J. 1993 Dec;20(6):653-9 [8267409.001]

[Cites] Am J Kidney Dis. 2000 Apr;35(4 Suppl 1):S132-40 [10766011.001]

[Cites] Scand J Caring Sci. 2006 Jun;20(2):223-8 [16756529.001]

[Cites] Am J Kidney Dis. 2001 Oct;38(4):839-46 [11576888.001]

[Cites] Int J Psychiatry Med. 1990;20(1):37-48 [2373593.001]

[Cites] Psychol Med. 1991 Feb;21(1):237-43 [2047501.001]

[Cites] J Clin Nurs. 2006 Apr;15(4):490-7 [16553763.001]

[Cites] BMJ. 1999 Jan 23;318(7178):217-23 [9915728.001]

[Cites] ANNA J. 1995 Oct;22(5):457-63, 481; discussion 464 [7487188.001]

[Cites] ANNA J. 1997 Oct;24(5):527-8, 531-8; discussion 539-40 [9392735.001]

[Cites] J Adv Nurs. 1999 Dec;30(6):1312-20 [10583641.001]

[Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]

[Cites] Int J Nurs Stud. 2002 Mar;39(3):269-77 [11864650.001]

[Cites] J Health Psychol. 1999 Mar;4(2):259-72 [22021484.001]

[Cites] J Palliat Med. 2006 Aug;9(4):977-92 [16910813.001]

[Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]

[Cites] Int J Nurs Pract. 1999 Sep;5(3):132-6 [10769621.001]

[Cites] ANNA J. 1996 Feb;23(1):19-26; discussion 27-8 [8702356.001]

[Cites] Adv Ren Replace Ther. 1998 Apr;5(2):98-108 [9554543.001]

[Cites] ANNA J. 1994 Aug;21(5):237-46, 257; discussion 247 [8080335.001]

[Cites] Clin Nurs Res. 2000 May;9(2):177-90 [12162241.001]

[Cites] J Nephrol. 2002 Jan-Feb;15(1):54-60 [11936427.001]

[Cites] Nephrol Nurs J. 2003 Feb;30(1):59-63 [12674951.001]

[Cites] Nephrol Nurs J. 2001 Aug;28(4):411-7, 419; discussion 418-9 [12143463.001]

[Cites] Palliat Med. 2005 Jul;19(5):389-96 [16111062.001]

[Cites] Clin Rehabil. 2004 Nov;18(7):776-84 [15573834.001]

[Cites] J Nephrol. 2004 Nov-Dec;17(6):841-50 [15593060.001]

[Cites] BMJ. 2004 May 8;328(7448):1099 [15130977.001]

[Cites] Nephrol Nurs J. 2000 Aug;27(4):383-91, 355; discussion 392, 405 [11276629.001]

[Cites] Soc Work Health Care. 2001;33(3-4):105-28 [11837357.001]

[Cites] Am J Kidney Dis. 2005 Jan;45(1):154-61 [15696455.001]

[Cites] J Nurs Manag. 2001 Jul;9(4):231-9 [11472513.001]

[Cites] Ann Behav Med. 1997 Fall;19(4):325-32 [9706357.001]

[Cites] EDTNA ERCA J. 2002 Jul-Sep;28(3):141-4 [12371739.001]

[Cites] Nurs Res. 1984 May-Jun;33(3):157-61 [6563533.001]

[Cites] J Palliat Med. 2005 Feb;8(1):79-85 [15662176.001]

[Cites] CANNT J. 2005 Jan-Mar;15(1):25-32 [15909774.001]

(PMID = 28656996.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Editorial

[Publication-country] England

[Keywords] NOTNLM ; caregiving/caring / end of life care / end-stage kidney disease / review

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

More than three million people of all ages are living with kidney disease in the UK.

The inter-relationship between kidney disease and many other conditions makes it of particular interest to nurses.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28085626.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Caring for patients after kidney transplantation.

It focuses on kidney transplantation and the nursing role in optimising long-term patient outcomes and quality of life.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27991203.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; British Nursing Index / Immunosuppressive medications; / Kidney transplantation; / Patient and graft survival

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Contrast-enhanced ultrasonography with microbubbles for successful screening of kidney tumours.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nephrol Dial Transplant. 2006 Apr;21(4):1104-8 [16431890.001]

[Cites] Eur Radiol. 2001;11(8):1316-28 [11519538.001]

[Cites] Circulation. 2006 Apr 11;113(14):1799-806 [16606801.001]

[Cites] J Ultrasound Med. 1999 Sep;18(9):581-8 [10478966.001]

[Cites] J Am Soc Nephrol. 1994 Mar;4(9):1661-9 [8011975.001]

(PMID = 28657014.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Advances in the cardiovascular assessment of patients with chronic kidney disease.

Cardiovascular mortality is grossly elevated in patients with chronic kidney disease (CKD), and is associated with a wide variety of structural and functional abnormalities.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nephrol Dial Transplant. 1988;3(2):174-80 [3140083.001]

[Cites] Physiol Rev. 1995 Jul;75(3):519-60 [7624393.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R226-31 [14500269.001]

[Cites] Biogerontology. 2000;1(3):235-46 [11707900.001]

[Cites] Ann Noninvasive Electrocardiol. 2008 Apr;13(2):191-207 [18426445.001]

[Cites] Br Heart J. 1981 Mar;45(3):248-63 [7008815.001]

[Cites] Ren Fail. 2008;30(7):701-9 [18704819.001]

[Cites] Am J Kidney Dis. 2004 Jun;43(6):966-75 [15168376.001]

[Cites] J Am Coll Cardiol. 1991 Mar 1;17(3):666-9 [1993786.001]

[Cites] Nephron Clin Pract. 2004;96(3):c82-7 [15056990.001]

[Cites] Acta Biomed. 2007;78(1):6-15 [17687811.001]

[Cites] Ann Cardiol Angeiol (Paris). 2004 Mar;53(2):79-90 [15222240.001]

[Cites] Kidney Int. 1999 Dec;56(6):2248-53 [10594802.001]

[Cites] J Am Soc Echocardiogr. 2006 Nov;19(11):1359-64 [17098139.001]

[Cites] Nephrol Dial Transplant. 2006 Mar;21(3):707-14 [16263735.001]

[Cites] Hypertension. 1996 Mar;27(3 Pt 1):330-8 [8698434.001]

[Cites] J Am Soc Nephrol. 2004 Apr;15(4):1029-37 [15034106.001]

[Cites] Ital Heart J. 2004 Aug;5(8):572-80 [15554027.001]

[Cites] Kidney Int. 2006 May;69(10):1839-45 [16508657.001]

[Cites] Prog Cardiovasc Dis. 2001 Mar-Apr;43(5):399-418 [11251127.001]

[Cites] J Nucl Med. 2005 Dec;46(12 ):2009-13 [16330564.001]

[Cites] Am J Crit Care. 2005 Jan;14(1):40-5 [15608107.001]

[Cites] Br J Anaesth. 2001 Aug;87(2):212-22 [11493492.001]

[Cites] Nephrol Dial Transplant. 2005 Sep;20(9):1848-53 [15972319.001]

[Cites] Circulation. 1991 May;83(5):1676-84 [1827056.001]

[Cites] J Hypertens. 2007 Jan;25(1):163-8 [17143188.001]

[Cites] Kidney Int. 2004 Sep;66(3):1212-20 [15327420.001]

[Cites] Circulation. 1997 May 20;95(10):2423-33 [9170406.001]

[Cites] Cardiol Clin. 2004 May;22(2):221-31 [15158936.001]

[Cites] J Am Coll Cardiol. 2005 Jun 21;45(12 ):2034-41 [15963406.001]

[Cites] Am J Kidney Dis. 2003 May;41(5):1016-25 [12722036.001]

[Cites] Clin Auton Res. 2004 Aug;14 (4):233-9 [15316840.001]

[Cites] Clin Physiol Funct Imaging. 2008 Jul;28(4):262-9 [18384622.001]

[Cites] Int Angiol. 1996 Mar;15(1):33-8 [8739534.001]

[Cites] Clin Sci (Lond). 1997 Apr;92(4):351-9 [9176033.001]

[Cites] Circulation. 1982 Dec;66(6):1146-9 [6754130.001]

[Cites] Kidney Int. 2000 Mar;57(3):1091-9 [10720961.001]

[Cites] Nephron. 1996;73(4):544-8 [8856249.001]

[Cites] Kidney Int. 2005 Jul;68(1):338-44 [15954925.001]

[Cites] Clin Auton Res. 1997 Dec;7(6):279-84 [9430798.001]

[Cites] J Am Soc Nephrol. 2006 May;17 (5):1460-5 [16597683.001]

[Cites] Am J Med. 1986 Oct;81(4):630-4 [3532789.001]

[Cites] Am J Kidney Dis. 1999 Jun;33(6):1080-90 [10352196.001]

[Cites] Nephrol Dial Transplant. 1998 Jun;13(6):1499-505 [9641182.001]

[Cites] Am J Cardiol. 1997 Apr 1;79(7):921-8 [9104907.001]

[Cites] Nephrol Dial Transplant. 2005 Jun;20(6):1140-7 [15827047.001]

[Cites] Nephrol Dial Transplant. 2004 Aug;19(8):2053-60 [15161953.001]

[Cites] Transplantation. 1990 Jan;49(1):100-3 [2300998.001]

[Cites] J Hypertens. 2003 Jan;21(1):3-12 [12544424.001]

[Cites] J Am Soc Nephrol. 2005 Dec;16(12):3687-93 [16280473.001]

[Cites] Kidney Int. 2006 Jul;70(1):157-64 [16710351.001]

[Cites] J Hypertens Suppl. 1999 Jun;17(2):S3-6 [10465060.001]

[Cites] Ann N Y Acad Sci. 2005 Jun;1043:299-307 [16037252.001]

[Cites] Cardiologia. 1994 Mar;39(3):193-7 [8039198.001]

[Cites] Am J Hypertens. 2005 Jul;18(7):995-1000; discussion 1016 [16053998.001]

[Cites] Int J Cardiol. 2005 Aug 18;103(2):168-74 [16080976.001]

[Cites] J Am Coll Cardiol. 2007 Dec 11;50(24):2285-90 [18068036.001]

[Cites] J Magn Reson Imaging. 2007 May;25(5):974-81 [17457797.001]

[Cites] Heart. 1999 Feb;81(2):111-3 [9922343.001]

[Cites] Nephrol Dial Transplant. 2003 Jul;18(7):1272-80 [12808161.001]

[Cites] N Engl J Med. 1991 Sep 19;325(12):836-42 [1875967.001]

[Cites] Kidney Int. 2002 Jul;62(1):166-71 [12081575.001]

[Cites] Am Heart J. 2003 Jul;146(1):183-8 [12851629.001]

[Cites] Am Heart J. 2004 Jun;147(6):1017-23 [15199350.001]

[Cites] J Appl Physiol (1985). 1993 May;74(5):2566-73 [8335593.001]

[Cites] Circulation. 2008 Mar 18;117(11):1478-97 [18316491.001]

[Cites] Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2687-96 [15297253.001]

[Cites] Nephron Clin Pract. 2008;108(2):c121-6 [18223317.001]

[Cites] J Am Coll Cardiol. 1990 Feb;15(2):459-74 [2137151.001]

[Cites] J Hypertens. 2006 Jan;24(1):143-50 [16331112.001]

[Cites] Diabetes. 1999 Jan;48(1):1-9 [9892215.001]

[Cites] Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H583-9 [17384132.001]

[Cites] Clin J Am Soc Nephrol. 2008 Jan;3(1):19-26 [18003765.001]

[Cites] Clin Auton Res. 1997 Jun;7(3):143-8 [9232359.001]

[Cites] Clin Physiol Funct Imaging. 2004 Nov;24(6):387-93 [15522049.001]

[Cites] Clin Physiol Funct Imaging. 2003 Mar;23(2):72-80 [12641600.001]

[Cites] Kidney Int. 2002 Dec;62(6):1921-32 [12427117.001]

[Cites] Diabetologia. 2004 Jul;47(7):1324-1330 [15243705.001]

[Cites] Hypertension. 1995 Aug;26(2):341-7 [7543454.001]

[Cites] J Hypertens. 2005 Apr;23(4):815-23 [15775787.001]

[Cites] J Hypertens. 2004 Jul;22(7):1371-80 [15201554.001]

[Cites] Circulation. 2005 Mar 8;111(9):1141-7 [15738351.001]

[Cites] Intensive Care Med. 2007 Jul;33(7):1191-4 [17458538.001]

[Cites] Am J Kidney Dis. 2006 May;47(5):830-41 [16632022.001]

[Cites] Trends Pharmacol Sci. 2006 Sep;27(9):503-8 [16876881.001]

[Cites] N Engl J Med. 1998 Jul 16;339(3):173-81 [9664095.001]

[Cites] J Am Coll Cardiol. 1999 Aug;34(2):441-7 [10440157.001]

[Cites] Kidney Int Suppl. 2008 Apr;(108):S119-24 [18379534.001]

[Cites] Diabetes Care. 2006 Dec;29(12):2654-9 [17130200.001]

[Cites] Metabolism. 2004 Feb;53(2):222-7 [14767875.001]

[Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1216-25 [17699351.001]

[Cites] J Hypertens. 2002 Jul;20(7):1423-9 [12131540.001]

(PMID = 28657024.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Editorial

[Publication-country] England

[Keywords] NOTNLM ; cardiovascular disease / chronic kidney disease / imaging / metabolic stress / monitoring

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis.

Here we report the case of a 45-year-old woman treated with CsA for alopecia universalis, who presented a severe myoglobinuric acute kidney injury following the concomitant use of simvastatin.

CsA and simvastatin therapy were stopped, and haemodialysis treatment was started (eight daily dialysis sessions) until sufficient kidney function was regained.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Acta Anaesthesiol Scand. 2005 Jul;49(6):859-64 [15954972.001]

[Cites] Nephron. 1994;68(1):57-62 [7991041.001]

[Cites] Kidney Int Suppl. 1995 Dec;52:S63-9 [8587287.001]

[Cites] Int J Tissue React. 2005;27(3):107-10 [16372476.001]

[Cites] Drug Metab Dispos. 1997 Oct;25(10):1191-9 [9321523.001]

[Cites] Int J Cardiol. 2005 May 11;101(1):9-17 [15860377.001]

[Cites] Ann Pharmacother. 2002 Feb;36(2):288-95 [11847951.001]

[Cites] Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004413 [18425901.001]

[Cites] Transplantation. 1994 Jul 15;58(1):42-5 [8036706.001]

[Cites] Am J Kidney Dis. 1996 Nov;28(5):631-67 [9158202.001]

[Cites] JAMA. 2003 Apr 2;289(13):1681-90 [12672737.001]

[Cites] Curr Opin Pediatr. 2009 Aug;21(4):475-80 [19502982.001]

[Cites] J Nephrol. 2002 May-Jun;15(3):317-9 [12113605.001]

(PMID = 28657046.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; acute kidney injury / ciclosporin / myoglobinuria / simvastatin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: Ian Jenkins has kidney cancer that has spread to his lungs.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28006323.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Renal atrophy secondary to chemoradiation treatment of abdominal malignancies.

: e15532 Background: Information on renal atrophy following abdominal chemoradiation (CRT) is limited.

METHODS: Patients who received concurrent CRT to the abdomen between 2002 and 2008 were identified for this study to evaluate change in renal size (RS) and function following CRT.

Renal function was assessed by serum creatinine and creatinine clearance (CrCl) using the Cockcroft-Gault formula.

The primarily irradiated kidney (PK) was defined as the kidney that received the greater mean kidney dose.

Age, gender, hypertension, diabetes, smoking, pre-RT CrCl, and pre-RT RS were not associated with renal atrophy at 12 months post RT.

Percent volumes of the PK receiving ≥10Gy (V₁₀), 15Gy (V₁₅), and 20Gy (V₂₀) were significantly associated with renal atrophy at 12 months post RT (p=0.0030, 0.0041, and 0.0046 respectively).

CONCLUSIONS: Significant detriments in PK size and renal function were seen following abdominal CRT.

V₁₀, V₁₅, and V₂₀ were associated with renal atrophy at 12 months post RT.

These observations can assist with renal dose constraints in CRT treatment planning for patients at increased risk for renal complications.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962316.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The first case had chronic kidney disease (CKD) Stage 3 and was exposed to 17.5 ml of gadobutrol.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Kidney Int. 2008 Jun;73(12):1413-8 [18401336.001]

[Cites] J Am Soc Nephrol. 2006 Sep;17(9):2359-62 [16885403.001]

[Cites] J Magn Reson Imaging. 2009 Dec;30(6):1249-58 [19938037.001]

[Cites] Lancet. 2000 Sep 16;356(9234):1000-1 [11041404.001]

[Cites] Semin Dial. 2008 Mar-Apr;21(2):129-34 [18225999.001]

[Cites] Nephrol Dial Transplant. 2009 Dec;24(12):3882-4 [19767635.001]

[Cites] Arch Dermatol. 2009 Feb;145(2):183-7 [19221265.001]

[Cites] Semin Dial. 2008 Mar-Apr;21(2):135-9 [18226001.001]

[Cites] Br J Dermatol. 2008 Feb;158(2):273-80 [18067485.001]

[Cites] Eur J Radiol. 2008 May;66(2):191-9 [18325705.001]

(PMID = 28657062.001).

[ISSN] 1753-0784

[Journal-full-title] NDT plus

[ISO-abbreviation] NDT Plus

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Keywords] NOTNLM ; chronic kidney disease / contrast-enhanced MRI / gadobutrol / nephrogenic systemic fibrosis

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Sue Wood, pictured, kidney transplant nurse at the Royal Free Hampstead NHS Trust, London, designed the device with her engineer husband and a friend who is a product designer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28026516.001).

[ISSN] 2047-9018

[Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of factors predicting loss of renal differential function on the operated kidney after laparoscopic partial nephrectomy.

: e16015 Background: Partial nephrectomy (PN) is now the gold standard for small renal mass of less than 4 cm since it prevents renal insufficiency that may occur with radical nephrectomy.

The impact of warm ischemis time (WIT) on the operated kidney's renal differential function (RDF) have been poorly studied in the litterature, especially when WIT is less than 30 minutes.

We evaluated the effect of WIT and other perioperative factors on RDF function assessed by pre- and post-operative renal scintigraphy.

METHODS: Between 2003 and 2008, 182 laparoscopic PN were performed by a single surgeon on patients with two kidneys.

Among those, 56 had a MAG3-lasix renal scintigraphy pre- and post-operatively between 7 and 14 days.

RESULTS: Medians for age, pre- op creatinine, pre-op GFR (Cockroft formula) and tumor CT-size were 61 years, 83 μM, 83,2 ml/min and 26 mm, respectively.

In multivariate analysis, low pre-operative RDF, WIT and intrarenal location of the tumor were associated with a statistically significant loss of RDF (p<0.05).

Age, pre-op GFR, tumor CT-size, diabetes and HTN did not predict loss in RDF.

CONCLUSIONS: We show that a WIT of less than 32 minutes optimizes the chances of preserving RDF of the operated kidney and that the rate of loss in RDF is higher above 32 minutes.

Finally, higher loss in RDF must be expected if the patient has a low pre-operative RDF and intrarenal location of the tumor.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962909.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Bevacizumab is a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat metastatic cancers of the colon, rectum, kidney, and breast.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2006 Mar 20;24(9):1363-9 [16446323.001]

[Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]

[Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]

[Cites] Clin Cancer Res. 2006 May 15;12(10):3124-9 [16707611.001]

[Cites] J Clin Oncol. 2005 Jun 1;23(16):3706-12 [15867200.001]

[Cites] JAMA. 2005 Feb 9;293(6):715-22 [15701913.001]

[Cites] Pathophysiol Haemost Thromb. 2003;33 Suppl 1:13-4 [12954992.001]

[Cites] Angiogenesis. 2004;7(3):193-201 [15609074.001]

(PMID = 29147218.001).

[ISSN] 1920-454X

[Journal-full-title] World journal of oncology

[ISO-abbreviation] World J Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Keywords] NOTNLM ; Bevacizumab / Brain stroke / Hypertension

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States.

: e17556 Background: RCC, the most prevalent kidney cancer, is a relatively rare malignancy that carries a poor prognosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963850.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence and long term prognosis of papillary renal cell carcinoma.

: e16020 Background: Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non clear-cell kidney cancer.

In this study we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC).

METHODS: We evaluated 744 patients who had undergone renal surgery for RCC between 1990 and 2005.

RESULTS: Both groups pRCC and ccRCC were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis.

Even though patients with pRCC presented more often with smaller (p = 0.039) and low grade tumours (p = 0.006), there was no statistically significant difference in tumour recurrence or tumour related death.

Moreover, looking at the whole cohort Kaplan-Meier curves revealed no differences regarding tumour specific survival between pRCC and ccRCC (p = 0.94; 5-year survival 78% vs. 77%).

However, we observed a trend towards an improved outcome for organ confined (pT1-2) cancer, but a significantly inferior prognosis for locally advanced stage (pT3-4) and/or metastatic papillary tumours at the time of renal surgery.

However, applying multivariate analysis including age, sex, and tumour grade, histology could neither be retained as a significant independent prognostic marker in the metastatic setting (p = 0.068, cox regression analysis) nor in a subgroup analysis focussing on patients with advanced cancer (pT3-4 and/or N+/M+; p = 0.064, cox regression analysis).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962984.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

: 5043 Background: An important goal of non-curative therapy for mRCC is tumor burden (TB) control.

However, the impact of tumor burden characteristics on clinical outcome has not been studied in mRCC pts treated with VEGF-targeted therapy.

CT scan images were re-reviewed from baseline, at the time of maximal tumor burden shrinkage (TS), at time of disease progression and at time of last assessment prior to death.

Sites of metastases included: lung (87%), mediastinal lymph nodes (52%), retroperitoneal lymph nodes (36%), adrenal (29%), bone (38%), liver (22%), pancreas (14%), kidney (7%), and brain (6%).

Total number of metastases <10 (p < 0.001) and tumor volume above the diaphragm <6.5 cm (p = 0.05) were independent positive predictors of OS.

At time of disease progression (PD), tumor location and pattern of progression were not associated with OS.

CONCLUSIONS: Tumor burden shrinkage and tumor burden at time of disease progression are associated with overall survival in pts with mRCC treated with sunitinib.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962954.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase I study of tumor treating fields (TTFields) in combination with pemetrexed for pretreated advanced non-small cell lung cancer.

: e18500 Background: TTFields (tumor treating fields) are low intensity, intermediate frequency, alternating electric fields which slow the growth of solid tumors in-vivo, and have shown promise in pilot clinical trials in patients with advanced solid tumors.

Patients with brain metastases were excluded, as were patients with abnormal marrow, kidney, liver or cardiac functions.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962405.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 7082 Background: In patients with PNH, lack of the glycophosphatidylinositol (GPI)-anchored terminal complement inhibitor CD59 on hematopoietic stem cells results in chronic intravascular hemolysis, kidney and pulmonary disorders, thrombosis, and shortened life span.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961475.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Pts with newly diagnosed AL involving ≤2 organs were assigned to MEL 100, 140 or 200mg/m2 with SCT, based on age, renal function and cardiac involvement.

RESULTS: Of 27 pts enrolled, organ involvement was kidney (63%), heart (44%), liver/GI (15%) and peripheral nervous system (7%); 33% have 2 organs involved.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960925.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 2068 Background: The primary purpose of this retrospective study was to determine the survival of patients with brain metastases following WBRT with regards to the influence of tumor type, age < 65 versus ≥ 65 (RPA RTOG prognostic factor) and recency of treatment date.

METHODS: From treatment records we identified 1,926 patients with brain metastases from solid tumors who were treated with WBRT at MVCC between February 1992 and March 2008.

RESULTS: We obtained dates of death for patients with lung (n=804), breast (n=457), colorectal (n=129), skin (n=119), kidney (n=82), and unknown primary (n=124) cancers.

42 patients were excluded from analysis as their tumor types were unspecified.

A heterogeneous group of 169 patients with a variety of other primary tumor types were also excluded from our primary analyses.

Log-rank analysis of age < 65 versus ≥ 65 demonstrated improved survival for the former for the colorectal, lung, and skin tumor types (p = 0.0048, 0.0001, and 0.0456 respectively).

This relationship did not reach significance for the breast, unknown primary, and renal cancer groups (p = 0.14, 0.13, and 0.06 respectively).

CONCLUSIONS: Our data validate age as an important prognostic factor for many tumor types with notable exceptions for as yet undetermined reasons.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964683.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 8107 Background: Everolimus (E) is an oral inhibitor of mammalian target of rapamycin (mTOR), a novel target for anti-cancer therapy that plays a central role in the PI3K/AKT signaling pathway and other pathways that mediate tumor growth, proliferation, and angiogenesis.

METHODS: Eligibility included SCLC with disease progression after up to 2 prior chemotherapy regimens, ECOG performance status (PS) 0-2, and adequate bone marrow, liver, and kidney function.

PI3K/AKT signaling pathway molecular biomarkers (AKT, pAKT, PTEN, P-S6, p-4E- BP1) will be evaluated on baseline tumor tissue.

Grade 3 toxicities included thrombocytopenia (2), neutropenia (2), infection (1), pneumonitis (1), fatigue (1), elevated transaminases (1), hyperglycemia (1), diarrhea (1), and acute renal failure due to dehydration from diarrhea and poor oral intake (1).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964287.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results.

QOL was measured by the Functional Assessment of Cancer Therapy-General (FACT-G), which has 4 subscales, the FACT-Kidney Symptom Index-15 item (FKSI-15), which includes a Disease-Related Symptoms (FKSI-DRS) subscale, and the EQ-5D questionnaire's utility index (EQ-5D Index) and visual analog scale (EQ-VAS).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964035.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States